| Project/Area Number |
22659054
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | The Institute of Physical and Chemical Research |
|---|
Principal Investigator |
SUZUKI Harukazu 独立行政法人理化学研究所, LSA要素技術開発グループ, プロジェクトディレクター (80333293)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥2,980,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥180,000)
Fiscal Year 2011: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2010: ¥2,200,000 (Direct Cost: ¥2,200,000)
|
|---|
| Keywords | プロモーター / CAGE / 薬剤作用 / トランスクリプトーム / 合剤 / 抗がん剤 / 抗ガン剤 |
|---|
| Research Abstract |
We tried to evaluate whether drug effects and/or combinatorial drug effects can be represented by promoter activity profiles. We found that effect(promoter profile) of Gefitinib, an inhibitor of mutated-EGFR in MCF7 cells, can be represented by those of U0126 and Wortmannin, the potent inhibitors of the downstream signal transductions. However, it was hard to precisely predict combinatorial drug effects(profiles) by using the single drug profiles. We concluded that we have established the promoter-based platform to analyze drug effects.
|
